Bupropion Hydrochloride Controlled-release
Phase 3Protein / enzyme
Bupropion Hydrochloride Controlled-release is one of 10 therapeutic programs targeting Hematopoietic and Lymphatic System Neoplasm. It is currently in Phase 3.
1
Indications
2
Total Trials
2
Active Trials
9
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
10 competitors in Hematopoietic and Lymphatic System Neoplasm
#DrugCompanyPhaseTrials
1Wellbutrin
GSKPhase 3
Trexall
Jazz PharmaceuticalsPhase 2
Retevmo
Eli LillyPhase 2
Veklury
GileadPhase 2
Cytosar
TevaPhase 2
Jakafi
IncytePhase 1
Bupropion Hydrochloride Controlled-release
UUniversity of Rochester NCORP Research Base
Phase 3
Therapeutic Hydrocortisone
EEastern Cooperative Oncology Group
Phase 2
Psilocybine
UUniversity of Zurich
Phase 2
Single Agent Therapy
TTheodore Brasky PhD
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cigarette Smoking-Related Carcinoma1 trial
Hematopoietic and Lymphatic System Neoplasm1 trial
Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue
Active, not recruiting·UUniversity of Rochester NCORP Research Base·Phase 3·NCT03996265·422 enrolled
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme
- Highest Phase
- Phase 3[1]